Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8692422 | 0.64 | MAPT (0.42) | MAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7258059 | 0.63 | MAPT (0.38) | MAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1447816 | 0.63 | MAPT (0.45) | MAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL235799 | 0.63 | MAPT (0.41) | MAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28222341 | 0.61 | MAPT (0.44) | MAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4153725 | 0.60 | MAPT (0.61) | MAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29059315 | 0.60 | MAPT (0.43) | MAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8060549 | 0.60 | MAPT (0.42) | MAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5530224 | 0.60 | MAPT (0.42) | MAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3873834 | 0.59 | MAPT (0.38) | MAPTTDP1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970482-B2 | Acetal compounds and therapeutic uses thereof | LIGAND PHARMACEUTICALS INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20200339551-A1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-10-29 | — | — | US | disclosed |
| EP-1678168-A4 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1611123-A4 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1678168-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1653938-A2 | METHODS OF TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH LXR AGONISTS | GLAXO GROUP LIMITED (GB) | 2006-05-10 | — | — | EP | disclosed |
| EP-1611123-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005039506-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005013946-A2 | METHODS OF TREATMENT INFLAMMATORY BOWEL WITH LXR AGONISTS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004091480-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-0932606-A4 | INHIBITORS OF PRENYL TRANSFERASES | BIOMEASURE INC (US) | 2000-01-19 | — | — | EP | disclosed |
| EP-0932606-A1 | INHIBITORS OF PRENYL TRANSFERASES | Biomeasure Incorporated (US) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998000409-A1 | INHIBITORS OF PRENYL TRANSFERASES | BIOMEASURE INCORPORATED (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339551-A1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | PYGL, GYS2, AADAC | MAPT 3292/4885TDP1 4686/4885ALDH1A1 50/4885 |
| US-11970482-B2 | Acetal compounds and therapeutic uses thereof | PYGL, GYS2, AADAC | MAPT 3292/4885TDP1 4686/4885ALDH1A1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.